Wave Life Sciences Ltd. (WVE) Financial Analysis & Valuation | Quarter Chart
Wave Life Sciences Ltd. (WVE)
WVEPrice: $7.49
Fair Value: 🔒
🔒score
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting prot... more
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces... more
Description
Shares
| Market Cap | $1.41B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | SG | CEO | Paul Bolno |
| IPO Date | 2015-11-11 | CAGR | — |
| Employees | 287 | Website | www.wavelifesciences.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
WVE chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.29B | P/E Ratio | -6.19 |
| Forward P/E | -5.59 | PEG Ratio | — |
| P/S Ratio | 6100235710295372889849856 | P/B Ratio | 5489907968194365481811968 |
| P/CF Ratio | -3449552138715917960871936 | P/FCF Ratio | -3367830431498838795616256 |
| EPS | $-1.21 | EPS Growth 1Y | -32.43% |
| EPS Growth 3Y | -54.49% | EPS Growth 5Y | -85.12% |
| Revenue Growth 1Y | 103.75% | Gross Margin | 0.89% |
| Operating Margin | -1.24% | Profit Margin | -1.12% |
| ROE | -0.73% | ROA | -4.71% |
| ROCE | 2.27% | Current Ratio | 2.51 |
| Quick Ratio | 2.51 | Cash Ratio | 2.28 |
| Debt/Equity | 0.16 | Interest Coverage | — |
| Altman Z Score | -40.44 | Piotroski Score | 2 |